Rasha Printz

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised adaptive security platform Halcyon on its $44 million Series A funding round, plus its $6 million secured term loan. Partner Derek Colla led the Cooley team advising Halcyon.

Read more

Cooley advised Razor’s Edge, a fund focused on high-growth technology investments in the national security market, in connection with its formation of a new platform, BlackSea Technologies. BlackSea builds and delivers intelligence, surveillance and reconnaissance capabilities, as well as other mission-tailored platforms for surface, subsurface and airborne operations across the naval domain. Cooley advised Razor’s Edge and BlackSea on the acquisition of Maritime Applied Physics Corporation in Baltimore, Maryland, and other BlackSea follow-on acquisitions.

Cooley separately advised Razor’s Edge in forming its new platform, Black Signal Technologies, with the acquisition of Blue Ridge Envisioneering, a developer of signal processing and electronic warfare solutions for national security customers. Cooley represented Black Signal in its follow-on acquisition of Silver Palm Technologies, a wireless engineering company specializing in products that support radio frequency and microwave distribution, signal conditioning and signal processing. 

Cooley also advised Veros Technologies, a technology company supporting critical cybersecurity missions for national security customers, in an equity investment by Razor’s Edge, and subsequently represented Veros in its acquisition of Bonfire Technologies, an elite cyber solutions company supporting similar customers and missions.

Cooley advised IonQ, a quantum computing hardware and software company, on its merger agreement with special purpose acquisition company dMY Technology Group III. Resulting in $650 million in gross proceeds, including $350 million from a fully committed PIPE, the transaction will make IonQ the first publicly traded pure-play hardware and software company in the quantum computing space. Partners Adam Ruttenberg, John McKenna, David Silverman, Jaime Chase and Mike Lincoln led the Cooley team advising IonQ.

Cooley advised the underwriters on Nanobiotix’s $113.3 million initial public offering of 8,395,000 ordinary shares (global offering) – including the offering of 6,540,000 American depositary shares, each representing one ordinary share, in the US (the US offering) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the US to certain investors (the European offering) – which includes the full exercise of the underwriters’ option to purchase additional shares. Jefferies acted as global coordinator and joint book-running manager for the global offering; Evercore Group and UBS Securities acted as joint book-running managers for the US offering; and Gilbert Dupont acted as manager for the European offering. Nanobiotix, whose securities now trade on the Nasdaq Global Select Market under the symbol NBTX, also trades on the Euronext Paris Market under the symbol NANO. Nanobiotix is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancers. Partners Brian Leaf, Div Gupta and David Boles led the Cooley team.